Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Let Us Learn About Prostate Cancer Together

Let Us Learn About Prostate Cancer Together

On Sunday, December 14, prostate cancer was discussed at the jointly organized Cancer School of Antalya Metropolitan Municipality and Medstar Cancer Center, in its 10th lesson.

Prof. Dr. Akın Yıldız, a Nuclear Medicine Specialist at Medstar Antalya Hospital who moderated the panel on early diagnosis and new treatment methods in prostate cancer, said in his opening speech that prostate enlargement and prostate cancer are serious problems for men, adding: “This disease progresses in parallel with age.” Emphasizing the importance of teamwork in diagnosis and treatment, Prof. Dr. Yıldız said: “In prostate cancer diagnosis and treatment, the urologist, medical oncologist, radiation oncologist, radiologist, interventional radiology specialist, pathologist and nuclear medicine specialist must work together and make decisions together.”

“Since prostate cancer is a disease of older age, mortality rates increase. Screening and early diagnosis are therefore very important.”

Providing information on screening and early diagnosis in prostate cancer, Assoc. Prof. Dr. Burak Hoşcan, a Urology Specialist at Medstar Topçular Hospital, said that prostate cancer is the most common cancer in men after lung cancer and ranks 2nd in deaths. Assoc. Prof. Dr. Burak Hoşcan explained that, for screening to be performed, the disease in question must have a high incidence, cause death and serious health problems, and also have an identifiable incubation period. He said: “The purpose of screening for prostate cancer is to detect the cancer while it is confined to the prostate and thereby reduce mortality.” Stating that prostate cancer develops with increasing age, Assoc. Prof. Dr. Hoşcan said: “Since prostate cancer is a disease of older age, mortality rates increase. Screening and early diagnosis are therefore very important.” Explaining that screening for this cancer is performed with a digital examination and blood PSA (prostate-specific antigen) measurement, Assoc. Prof. Dr. Hoşcan said: “According to data from studies conducted to date, there is strong evidence that prostate cancer screening reduces disease progression. Following the widespread introduction of PSA, from 1993 to 2003, mortality fell by 32,5%. PSA should be performed in all men over 50 and in men over 40-45 with a family history of prostate cancer.”

“The MR-TRUS fusion system, which combines MR-guided biopsy with transrectal ultrasound and is a more practical method, appears likely to enter daily use.”

Dr. Sagfettin Kaya, a Urology Specialist and Surgeon at Medstar Antalya Hospital, provided information on who should undergo biopsy for prostate cancer and described innovations in biopsy methods. “Prostate biopsy is performed when hardness or a nodule is detected during a digital prostate examination, or when the PSA (prostate-specific antigen) level is high,” said Dr. Kaya. He explained that the most commonly used prostate biopsy method is transrectal ultrasound biopsy (taking a sample from the prostate by entering through the rectum under ultrasound guidance). Stating that biopsy is performed without general anesthesia in daily practice, Dr. Kaya said: “Sensitivity is reduced by applying a lubricating, pain-reducing gel to the rectum, and pain is then substantially relieved by injecting local anesthetic around the prostate.” Dr. Kaya stated that prostate biopsy should not be performed in the presence of a serious bleeding tendency, an active and painful problem in the anal region, impairment of the body’s defense system, or active inflammation of the prostate. He emphasized that, besides indicating whether cancer is present, biopsy provides information about the proliferation and spread rate of cancer cells, the percentage of tumor in the samples, spread to nerves, and the presence of precancerous cells. Explaining that a method called saturation biopsy has been performed for the past 10 years, Dr. Kaya said: “In this procedure, we saturate the prostate with biopsies. Performed under general anesthesia, the procedure again uses transrectal ultrasound, with more than 20 biopsies taken from all quadrants of the prostate.” Dr. Kaya said: “The MR-TRUS fusion system, which combines MR-guided biopsy with transrectal ultrasound and is a more practical method, appears likely to enter daily use in the near future,” adding: “Adverse effects of biopsy, such as bleeding, infection and inability to urinate, are temporary problems.”

“Robotic surgery is a rapidly developing technique in prostate cancer treatment.”

Assoc. Prof. Dr. Mutlu Ateş, a Urology Specialist at Memorial Antalya Hospital, provided information on innovations in surgical methods for prostate cancer treatment. Stating that prostate cancer is a disease of older age, Assoc. Prof. Dr. Ateş said: “Turkey currently has a young population. However, in 2023 we will be an older country. This means that, together with an increasing older population, there will be more prostate cancer.” Emphasizing that treatment methods are developing alongside early diagnosis methods, Assoc. Prof. Dr. Ateş said: “Especially in early-stage prostate cancer, radical prostatectomy performed in surgery can be combined with hormone treatment, or with radiotherapy and hormone treatment.” He continued: “In radical prostatectomy, there are roughly two methods: retropubic (open), perineal (open), or laparoscopic robotic (closed). The procedure is performed by completely removing the prostate, which maintains continuity of the urinary tract, and replacing it with a catheter to maintain urinary tract continuity. When removing the tumor, usually located in the outer shell of the prostate, it is important not to damage the nerves in the same region. This minimizes postoperative complications. Since the muscles controlling urinary retention are at the beginning and end of the prostate, we must also preserve these muscles well during surgery.” Emphasizing that the most positive aspect of radical prostatectomy is complete elimination of these cancer cells from the tissue, Assoc. Prof. Dr. Ateş said: “It positively affects the course of the disease and provides psychological benefit; if we can preserve the nerves, erections are preserved, and because PSA measurements are very low, the values can be monitored more effectively.” He continued: “The closed surgical method in radical prostatectomy is called ‘minimally invasive surgery.’ Open surgery gradually gave way to laparoscopic prostatectomy, and most recently robotic prostatectomy emerged.” Assoc. Prof. Dr. Ateş said: “In both laparoscopic prostatectomy and robotic prostatectomy, we reach the target muscle by opening a tunnel and placing a tube. This causes the least harm to the patient,” adding: “Unlike laparoscopic prostatectomy, robotic radical prostatectomy is an operation performed with the help of a robot controlled by the surgeon.” Continuing with “Robotic surgery is a rapidly developing technique,” Assoc. Prof. Dr. Ateş said: “While the target region is currently entered through 4-5 openings, in the future it will be entered through a single opening. This single opening will be the navel. The robot arm entering through the navel is expected to bend like a snake inside, find the target organ and perform the operation. Closed surgery has been shown to cause less harm to the patient, while robotic surgery has a more positive effect than laparoscopic prostatectomy on life-affecting issues such as urinary control and erections, and improves quality of life. However, its cost is much higher than open surgery and laparoscopic prostatectomy.” He concluded: “Robotic surgery may not be preferred in terms of cancer control, but it is recommended in terms of the patient’s quality of life (urinary control and erections).”

“The most commonly used methods worldwide for prostate cancer treatment are still surgery and radiotherapy. The main reason is that the complication rate is still not sufficiently low when we try to treat the entire prostate. We therefore use interventional treatments to detect cancer early, treat the tumor within the prostate rather than the entire prostate, and then monitor the patient.”

Prof. Dr. Saim Yılmaz, an Interventional Radiology Specialist at Medstar Antalya Hospital, described nonsurgical interventional treatment methods for prostate cancer. Prof. Dr. Yılmaz began: “Cryoablation (freezing), applied by entering with a needle through the region we call the ‘perineum—that is, between the penis and anus’—along with nanoknife, laser and radiofrequency treatments, and HIFU, applied without a needle through the rectum using sound waves from the region just inside the anus, are interventional treatments.” Prof. Dr. Yılmaz emphasized that methods using heat, such as laser, radiofrequency and HIFU, are at the experimental stage in prostate cancer treatment. Stating that freezing, or cryoablation, the most commonly used method in prostate cancer, is ultrasound-guided, Prof. Dr. Yılmaz said that cryoablation is also performed under MR guidance and that some specialists consider this form of application more advantageous. Noting the increasing popularity of the procedure called Nanoknife in recent years, Prof. Dr. Yılmaz said: “The characteristic of this method is that it causes less damage to the nerves in the region because it treats with electric current without burning.” Explaining that another method used quite frequently in prostate cancer is HIFU, Prof. Dr. Yılmaz said: “Sound waves are focused with the aid of a lens. The temperature within this focus reaches 80-100 degrees. However, it burns only the focus, not the area where it passes through the skin.” Stating that surgery and radiotherapy are treatments used for prostate cancer and provide positive results, but that some adverse effects reducing quality of life, such as urinary control and erection problems, are encountered, Prof. Dr. Yılmaz said: “The expectation from interventional treatments is fewer of these adverse effects and success comparable to the other treatments.” Emphasizing that interventional treatments (cryoablation and HIFU) were first used successfully in patients whose cancer recurred after radiotherapy, Prof. Dr. Yılmaz said: “This is because repeat radiotherapy is problematic in such patients. Surgical methods also have many adverse effects. Therefore, interventional treatments began to be used as initial treatment for prostate cancer, as alternatives to radiotherapy and surgery.” Prof. Dr. Yılmaz stated that, because this is still a new treatment method, long-term results compared with radiotherapy and surgery have not yet become clear, and said: “Oncological results over 5-10 years show that interventional treatments are similar to surgery and radiotherapy. However, adverse effects (such as urinary incontinence, erection problems and narrowing of the urinary channel) occur less often. Despite this, the most commonly used methods worldwide for prostate cancer treatment are still surgery and radiotherapy. The main reason is that the complication rate is still not sufficiently low when we try to treat the entire prostate. We therefore use interventional treatments to detect cancer early, treat the tumor within the prostate rather than the entire prostate, and then monitor the patient.” Prof. Dr. Yılmaz concluded: “The new and developing Multiparametric MR correctly shows 90% of prostate cancers and indicates which detected prostate cancers may cause problems in the future and which definitely require treatment. The future goal in prostate cancer is more extensive use of the Multiparametric MR technique, image-guided interventional treatments and biopsy under direct visualization of the target.”

“What matters to us is delivering radiotherapy to the right place at the right time! Cancer patients now experience fewer adverse effects from radiotherapy, so their quality of life improves, they live longer, and new treatment strategies can be tried.”

Assoc. Prof. Dr. Berrin Pehlivan, a Radiation Oncology Specialist at Medstar Antalya Hospital, provided information on radiotherapy methods in prostate cancer treatment. Assoc. Prof. Dr. Pehlivan said that prostate cancer is common and that in a very large proportion of patients it continues for many years without any findings, without treatment and without affecting life, adding: “For this reason, we treat only a very small proportion of prostate cancers. When we do treat them, we achieve very good results, and our treatment method is easy.” Assoc. Prof. Dr. Pehlivan said: “Radiotherapy may be somewhat complicated for the team delivering it, but it is a very simple treatment method for the patient receiving it. This is because no pain or discomfort is felt during treatment. All the patient does is lie motionless in the machine.” Explaining that patients with prostate cancer presenting for radiotherapy are divided into risk groups according to PSA values and biopsy results, Assoc. Prof. Dr. Pehlivan said: “If the patient is in the low-risk group, we treat with surgery or radiotherapy. Before deciding, of course, a multidisciplinary approach is needed, and treatment should be determined by obtaining the opinions of all specialist physicians rather than only those in radiotherapy or surgery.” Explaining that patients with intermediate-risk prostate cancer receive radiotherapy concurrently with hormone treatment starting 1-2 months before radiotherapy and continuing for 3-6 months, Assoc. Prof. Dr. Pehlivan said: “For patients in a higher-risk group, we recommend radiotherapy and hormone treatment for at least 2 years afterward.” Stating that radiotherapy provides results equivalent to surgery, is easily tolerated and has minimal impact on the patient’s quality of life, Assoc. Prof. Dr. Pehlivan said: “The location of prostate cancer is very important to us in treatment planning. The final part of the bowel lies behind the prostate, and the urinary bladder lies in front of and slightly above it. We make calculations with millimetric precision to protect the bowel behind it and the bladder in front of it properly.” Assoc. Prof. Dr. Pehlivan noted that the X-rays delivered can also damage some normal tissues as they leave the body, but new technology minimizes this and results in fewer adverse effects. Continuing with “What matters to us is delivering radiotherapy to the right place at the right time,” Assoc. Prof. Dr. Pehlivan said that the area requiring irradiation and the organs requiring protection must be known very well. She said: “With new technology, we can now do these things very well. As a result, cancer patients now experience fewer adverse effects, their quality of life improves, they live longer, and new treatment strategies can be tried.” Underlining the importance of attending healthcare centers capable of delivering intensity-modulated radiotherapy, a standard technique, Assoc. Prof. Dr. Pehlivan emphasized that cancer patients should choose healthcare centers where they feel comfortable with a specialist team that knows its work well and is equipped in technical and medical matters.

“There is truly great potential in prostate-specific molecular diagnostic and treatment methods for disseminated disease. In particular, it appears that substantial successes will be achieved with the isotopes we call lutetium and radium.”

Prof. Dr. Akın Yıldız, a Nuclear Medicine Specialist at Medstar Antalya Hospital, provided information on molecular diagnostic and treatment methods in prostate cancer. Explaining how prostate cancer is identified when it spreads to distant regions and what new treatment methods are available at this stage, Prof. Dr. Yıldız said that, in distant spread, cancer is first seen in the bones. Stating that whole-body bone scintigraphy is performed to investigate bone spread, Prof. Dr. Yıldız said: “If the Gleason Score in the pathology report is 7 or higher, or PSA values are higher than 20, the risk of cancer spread is considered high and patients undergo bone scintigraphy.” He also noted the existence of a Bone PET method used only for bones, saying: “Bones use calcium fluoride. Therefore, with a PET method using the developed fluoride in radioactive form, the presence of disease in bones is seen much better than with bone scintigraphy. In standard PET-CT, glucose, or sugar, is administered to the body to image regions containing cancer. Prostate cells do not use much sugar. Therefore, conventional PET-CT imaging is generally unsuccessful in imaging prostate cancer and is not often preferred.” However, mentioning new molecular imaging methods, Prof. Dr. Yıldız said: “The prostate does not like sugar, but it likes amino acid proteins. There is a new imaging method using choline amino acids called Choline PET. This imaging, not yet performed in our country, requires very specialized technologies. However, its rate of identifying prostate cancer is low, at around 70%.” Explaining that another new imaging method used in certain places worldwide is PSMA PET, Prof. Dr. Yıldız said: “PSMA PET, which we call prostate-specific membrane antigen, is a method that takes advantage of a protein found on prostate cancer cells, captures that protein and images it.” Stating that certain radioactive treatments are also being considered alongside imaging techniques, Prof. Dr. Yıldız said: “Not only radioactive treatments but also other treatments such as targeted virotherapy, PSMA vaccination and prodrug activation are being rapidly developed. In the near future, certain particles we call PSMA-targeted nanoparticles will also target and destroy the cancerous points that have been imaged. However, these methods are still very new.” Prof. Dr. Yıldız stated that one of the molecular treatments they currently use is samarium. Explaining that an isotope is administered which reaches cancer that has spread to the bones, Prof. Dr. Yıldız said that samarium reduces bone pain and provides partial benefit against the disease, although it is not very effective. Prof. Dr. Yıldız said: “Radium 223, called Xofigo and not yet available in Turkey, travels only to disease sites in the bones, destroys those regions and can contribute to the patient’s survival. In another treatment that has only recently begun to be performed, the isotope we call lutetium targets the protein specific to prostate cancer and that cell.” Prof. Dr. Yıldız concluded: “In summary, there is truly great potential in prostate-specific molecular diagnostic and treatment methods for disseminated disease. In particular, it appears that substantial successes will be achieved with the isotopes we call lutetium and radium.”

“The main problem in cancer was that the cells of our body’s immune system did not recognize cancer cells. Certain antibodies developed for this reason enabled cancer cells to be recognized. With this revolutionary development in 2014, I can say that a breakthrough is about to occur in the treatment of many cancer types, including prostate cancer.”

Dr. Ayşegül Kargı, a Medical Oncology Specialist at Medstar Antalya Hospital, provided information on chemotherapy, hormone treatment and vaccines in prostate cancer. Dr. Kargı began: “The prostate gland needs androgens, which we call testosterone, to grow, develop and function. Some androgens secreted in men are produced in the testes, a large proportion in the adrenal glands, and, in patients with cancer, also by the tumor in the prostate gland and its metastases. Hormonal treatments we call anti-androgens have an important place in prostate cancer treatment.” Stating that patients with advanced prostate cancer respond well to hormone treatment, with certain symptoms such as bone pain decreasing by 70-80% and tumor shrinkage of 50%, Dr. Kargı said: “Hormone treatment is the most commonly used treatment method in prostate cancer and still maintains its place as first-line treatment in disseminated disease.” Despite all these positive effects, hormonal treatment does not always succeed, Dr. Kargı said: “After a while, many patients receiving hormonal treatment develop resistance and the disease progresses. In this situation, we begin chemotherapy.” Stating that the only chemotherapy drug used in prostate cancer treatment until 2004 was mitoxantrone, which did not greatly prolong patients’ lives, Dr. Kargı said: “In 2004, a drug we call docetaxel was developed and provided a survival advantage. We therefore began using taxane-group drugs after hormonal treatment in prostate cancer.” Dr. Kargı said: “Since 2010, within the past 4 years, new hormonal treatments, new chemotherapy drugs, vaccine treatments emitting alpha waves, and monoclonal antibody treatments acting through the immune system have been discovered in prostate cancer.” She continued: “With a new development in 2014, we saw a significant increase in survival when chemotherapy was combined with hormonal treatment, particularly when bone metastases number more than 4 or there is spread to internal organs. We can therefore use chemotherapy together with hormonal treatment in such situations.” Dr. Kargı stated that the drugs used in prostate cancer chemotherapy are docetaxel and cabazitaxel, while abiraterone is used as hormonal treatment, and that another hormonal treatment called enzalutamide would begin to be used in our country very shortly. Dr. Kargı emphasized: “The main problem in cancer was that the cells of our body’s immune system did not recognize cancer cells. Certain antibodies developed for this reason enabled cancer cells to be recognized. With this revolutionary development in 2014, I can say that a breakthrough is about to occur in the treatment of many cancer types, including prostate cancer.” Dr. Kargı said that, in addition to hormone and chemotherapy options, vaccine treatment aimed at eliminating tumor cells had also shown a survival advantage in prostate cancer. She stated that the vaccine, which can be administered to patients with metastatic prostate cancer, prolongs average survival, but is not yet covered by reimbursement in our country.

Until we meet at another session of the “Cancer School,” such a successful social responsibility project aimed at increasing public awareness..

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Let Us Learn About Prostate Cancer Together

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy